ArticleFrontiers in nutrition2025
1-Deoxynojirimycin with theaflavins ameliorates high-fat diet-induced insulin resistance in mice by modulating the gut microbiota.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Effects of 1-Deoxynojirimycin-Enriched Mulberry Extract on Liver and Gut Health in Broilers Under a High-Fat Diet.Animals : an open access journal from MDPI · 2026Article
- Nutritional Modulation of Epigenetic Responses to Heat Stress in Farm Animals: Evidence, Limitations and Perspectives.Animals : an open access journal from MDPI · 2026Review
- Hesperidin: a bioflavonoid with broad therapeutic promise.Inflammopharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study investigated the ameliorative effects of combined 1-DNJ and TFs on IR in mice through gut microbiota modulation. Methods: An HFD-induced IR model was established in male mice, which were subsequently divided into Control, Model, 1-DNJ (200 mg/kg·bw/day), TFs (100 mg/kg·bw/day), and 1-DNJ + TFs (200 + 100 mg/kg·bw/day) groups for daily oral administration over 11 consecutive weeks. The ameliorative effects were evaluated by examining biochemical parameters in serum and histopathological changes in the liver pancreatic and colon. Mechanistic insights were elucidated through 16S rRNA gene sequencing of fecal samples and untargeted metabolomics analysis of intestinal contents. Results: Interventions with 1-DNJ, TFs, or thecombination effectively reduced blood glucose levels and improved insulin sensitivity. The combined treatment demonstrated superior efficacy, decreasing circulating levels of LPS, IL-6, and TNF-α, alleviating hepatic lipid accumulation, and reducing colon tissue barrier damage. Furthermore, the combined intervention profoundly modulated the gut microbiota, characterized by an increased abundance of beneficial bacteria (e.g., Muribaculaceae, Lachnospiraceae_NK4A136_group, Alloprevotella) and a reduction in harmful genera (e.g., Roseburia, Intestinimonas). These microbial shifts were concomitantly associated with significant alterations in intestinal metabolic pathways, including sphingolipid metabolism, necroptosis, glycerophospholipid metabolism, the pentose phosphate pathway, pentose and glucuronic acid interconversion, and tyrosine metabolism. Conclusion: The combined administration of 1-DNJ and TFs demonstrated superior efficacy in ameliorating HFD-induced IR compared to individual components, with gut microbiota modulation playing a pivotal role. These findings position 1-DNJ and TFs as promising natural candidates for functional food development targeting metabolic health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.